Zidesamtinib

N/A

Report date: 2025/11/24 14:40:09
NME

Base Information

Drug NameZidesamtinib
Drug Alias NameNVL-520NUV-520NUVL 520
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitors
TargetsProto-oncogene tyrosine-protein kinase ROSAnaplastic lymphoma kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesNuvalent Inc
China Registration ClassN/A

Develop Information

Active CompaniesNuvalent Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A